Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice

Vaccine

Volumn 25, Issue 12, 2007, Pages 2168-2172

  Gomes, Daniel Cláudio de Oliveira ^a   Pinto, Eduardo Fonseca ^a   Melo, Luiz Dione Barbosa de ^a   Lima, Wallace Pacienza ^a   Larraga, Vicente ^b   Lopes, Ulisses Gazos ^a   Rossi Bergmann, Bartira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

DNA; Intranasal; LACK; Leishmania chagasi; Leishmania infantum; Vaccine; Visceral leishmaniasis

Indexed keywords

ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; LACK PROTEIN; NAKED DNA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; EXPRESSION VECTOR; GENE; GENETIC CODE; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; LACK GENE; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SPLEEN CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, PROTOZOAN; DNA, PROTOZOAN; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PLASMIDS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; TREATMENT OUTCOME;

EID: 33846876561     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.060     Document Type: Article

References (31)

1. World Health Organization. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. The World Health Report. Geneva: WHO; 2002. p. 192-97.
2. Moreira E.D., de Souza V.M.M., Sreenivasan M., Nascimento E.G., and de Carvalho L.P. Assessment of an optimized dog-culling program in the dynamics of canine Leishmania transmission. Vet Parasitol 122 4 (2004) 245-252
3. Sundar S., and Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 16 (2005) 2821-2829
4. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
5. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., et al. Expression cloning of a protective Leishmania antigen. Science 268 5210 (1995) 563-566
6. Okuno T., Takeuchi M., Matsumoto Y., Otsuka H., and Matsumoto Y. Pretreatment of Leishmania homologue of receptors for activatead C kinase (LACK) promotes disease progression caused by Leishmania amazonensis. Exp Anim 51 4 (2002) 335-341
7. Coelho E.A., Tavares C.A., Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71 7 (2003) 3988-3994
8. Launois P., Maillard I., Pingel S., Swihart K.G., Xenarios I., Acha-Orbea H., et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 161 11 (1997) 6156-6163
9. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 7 (1997) 1137-1147
10. Ahmed S.B., Bahloul C., Robbana C., Askri S., and Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22 13-14 (2004) 1631-1639
11. Dumonteil E., Maria Jesus R.S., Javier E.O., and Maria Del Rosario G.M. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21 17-18 (2003) 2161-2168
12. Marques-Da-Silva E.A., Coelho E.A.F., Gomes D.C.O., Vilela M.C., Masioli C.Z., Tavares C.A.P., et al. Intramuscular immunization with p36 (LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol Res 98 1 (2005) 67-74
13. Melby P.C., Yang J., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 8 (2001) 4719-4725
14. Dondji B., Perez-Jimenez E., Goldsmith-Pestana K., Esteban M., and McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73 8 (2005) 5286-5289
15. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
16. Czerkinsky C., Anjuere F., McGhee J.R., George-Chandy A., Holmgren J., Kieny M.P., et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 170 (1997) 197-222
17. Takagi H., Hiroi T., Yang L.J., Tada Y., Yuki Y., Takamura K., et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci USA 102 48 (2005) 17525-17530
18. Arakawa T., Komesu A., Otsuki H., Sattabongkot J., Udomsangpetch R., Matsumoto Y., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 73 8 (2005) 7375-7380
19. Chabot S., Brewer A., Lowell G., Plante M., Cyr S., Burt D.S., et al. A novel intranasal Protollin (TM)-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23 11 (2005) 1374-1383
20. Pinto E.F., Cortezia M.M., and Rossi-Bergmann B. Interferon gamma-induceing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21 25-26 (2003) 3534-3541
21. Pinheiro RO, Pinto EF, Guedes HLM, Filho OA, Mello KA, Saraiva EM, Mendonça SCF, Bergmann BR. Protection against cutaneous leishmania by intranasal vaccination with lipophosphoglycan. Vaccine 2006, doi:10.1016/j.vaccine.2006.05.093, in press.
22. Pinto E.F., Pinheiro R.O., Rayol A., Larraga V., and Rossi-Bergmann B. Intranasal vaccination agaist cutaneous leishmaniasis using a particulated leishmanial antigen or LACK-DNA. Infect Immun 72 8 (2004) 4521-4527
23. Tumang M.C., Keogh C., Moldawer L.L., Helfgott D.C., Teitelbaum R., Hariprashad J., et al. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 153 2 (1994) 768-775
24. Jahnsen F.L., Gran E., Haye R., and Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. Am J Respir Cell Mol Biol 30 1 (2004) 31-37
25. Alignani D., Maletto B., Liscovsky M., Ropolo A., Moron G., and Pistoresi-Palencia M.C. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 77 6 (2005) 898-905
26. Farkas L., Kvale E.O., Johansen F.E., Jahnsen F.L., and Lund-Johansen F. Plasmacytoid dendritic cells activate allergen-specific TH2 memory cells: modulation by CpG oligodeoxynucleotides. J Allergy Clin Immunol 114 2 (2004) 436-443
27. Alexander J., Carter K.C., Al-Fasi N., Satoskar A., and Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30 10 (2000) 2935-2943
28. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
29. Mcghee J.R., Lamm M.E., and Strober W. Mucosal immune responses. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., and Mcghee J.R. (Eds). Mucosal immunology. 2nd ed. (1999), Academic Press, San Diego 485-506
30. Julia V., McSorley S.S., Malherbe L., Breittmayer J.P., Girard-Pipau F., Beck A., et al. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J Immunol 165 10 (2000) 5637-5645
31. Oh Y.K., Kim J.P., Hwang T.S., Ko J.J., Kim J.M., Yang J.S., et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 19 31 (2001) 4519-4525